GC Biopharma co-developed the anthrax vaccine along with the Korea Disease Control and Prevention Agency. Novikov Aleksey Shutterstock.com.

GC Biopharma has sought marketing approval from the Korean Ministry of Food and Drug Safety (MFDS) for anthrax vaccine GC1109.

The company co-developed the vaccine along with the Korea Disease Control and Prevention Agency.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GC1109 has a protective antigen as its active pharmaceutical ingredient, created using recombinant DNA technology. This approach involves two types of proteins, comprising anthrax toxin, lethal factor and oedema factor. 

On obtaining approval, GC1109 will become the first recombinant anthrax vaccine globally.

A Phase II clinical trial analysed the safety and immunogenicity of the intramuscular dose of GC1109 in healthy subjects. 

See Also:

Findings showed that the vaccine-induced antibodies neutralise anthrax toxins.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Vaccine-associated adverse drug reactions or solicited adverse events were in line with those observed in the placebo arm.

GC Biopharma stated: “We believe in the significance of our journey to localise the anthrax vaccine in terms of securing vaccine sovereignty while promoting public health and national security. 

“GC Biopharma will continue to lead the localisation of critical medicines and contribute to the stable supply of basic medical supplies as it has been doing for other vaccines and blood products since the foundation of the company.”

Classified as a Class 1 infectious disease under the Infectious Disease Control and Prevention Act, anthrax is caused by Bacillus anthracis.

GC Biopharma and KDCA have been collaborating since 2002 to develop a recombinant anthrax vaccine.